Sean Scanlan compensation by year
TREACE MEDICAL CONCEPTS Summary Compensation Table · the one fiscal year held| Component | FY2025 |
|---|---|
| Salary | $446,370 |
| Bonus | $0 |
| Stock awards | $1,849,688 |
| Option awards | $0 |
| Non-equity incentive | $0 |
| Pension and deferred compensation | $0 |
| All other | $14,837 |
| Total | $2,310,894 |
Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: TREACE MEDICAL CONCEPTS, INC. DEF 14A filed April 6, 2026, accession 0001630627-26-000005, and prior-year filings. Open the filing on EDGAR.
Equity holdings
unvested awards at FY2025 year-end| Type | Unvested units | Value at year-end | Exercise price |
|---|---|---|---|
| RSU | 675,000 | $890,203 | — |
| RSU | 247,500 | $606,375 | — |
| RSU | 83,437 | $511,043 | — |
| RSU | 140,625 | $344,531 | — |
| RSU | 80,600 | $197,470 | — |
| RSU | 64,782 | $158,716 | — |
| RSU | 48,768 | $119,482 | — |
| PSU | 46,875 | $114,844 | — |
| PSU | 32,525 | $79,686 | — |
| RSU | 11,462 | $28,082 | — |
| PSU | 10,000 | $24,500 | — |
| RSU | 1,643 | $4,025 | — |
Per the Outstanding Equity Awards at Fiscal Year-End table in TREACE MEDICAL CONCEPTS, INC.'s FY2025 proxy; value at the fiscal year-end close, as the company printed it. The 12 largest of 17 award rows shown.
Insider transactions since the last proxy
1 Form 4 line since the FY2025 proxy (filed April 6, 2026)current to 2026-09-24 · updated nightly
| Date | Transaction | Plan | Shares | Price | Held after |
|---|---|---|---|---|---|
| 2026-08-09 | Tax withholding | — | 9,814 | $0.00 | 679,863 |
The 1 most recent of 1 lines, each as reported on the Form 4. "10b5-1" marks a trade the filing reports under a pre-arranged trading plan. View every Form 4 filing on EDGAR →
TREACE MEDICAL CONCEPTS’s named executive officers, FY2025
as the company reported each| Named executive officer | Role | FY2025 total |
|---|---|---|
| John Treace | Chief Executive Officer, Founder and Board Chair | $5,405,190 |
| Mark Hair | Chief Financial Officer | $5,157,046 |
| Sean Scanlan · this page | Chief Innovation Officer | $2,310,894 |
| Scot Elder | Chief Legal & Compliance Officer, Corporate Secretary | $2,123,983 |
| Gaetano Guglielmino | Chief Commercial Officer | $468,536 |
The full TREACE MEDICAL CONCEPTS compensation record
free company briefThis page is one person within TREACE MEDICAL CONCEPTS's record. The company brief lists every named executive, each linking to their own page.
Compensation, the day it’s disclosed
The CompBrief Daily Digest lists the newest executive and director compensation disclosures as companies file them. Or order TREACE MEDICAL CONCEPTS's full Executive Compensation Report with peer benchmarking.
How this record is built
Every figure on this page is one figure from a public SEC filing, printed as the filing states it and cited to the document. Compensation totals are TREACE MEDICAL CONCEPTS's own disclosed totals, not summed by Velarion. Insider transactions are read from Form 4 filings and cover every line filed since the most recent proxy. Nothing is estimated by Velarion; where the company does not disclose a value the cell reads "—", and a section appears only where the company discloses the data. Corrections: records@velarion.ai.
Velarion Pro: every company page, peer tools and exports, one seat